79 related articles for article (PubMed ID: 17191749)
1. [Medication of the month. Duloxetine (Cymbalta)].
Pitchot W
Rev Med Liege; 2006 Nov; 61(11):787-90. PubMed ID: 17191749
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and continuation treatment of major depressive disorder.
Bochsler L; Olver JS; Norman TR
Expert Rev Neurother; 2011 Nov; 11(11):1525-39. PubMed ID: 22014130
[TBL] [Abstract][Full Text] [Related]
3. Preclinical discovery of duloxetine for the treatment of depression.
Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E
Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Chalon SA; Granier LA; Vandenhende FR; Bieck PR; Bymaster FP; Joliat MJ; Hirth C; Potter WZ
Neuropsychopharmacology; 2003 Sep; 28(9):1685-93. PubMed ID: 12784100
[TBL] [Abstract][Full Text] [Related]
6. Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models.
Pereira P; Gianesini J; da Silva Barbosa C; Cassol GF; Von Borowski RG; Kahl VF; Cappelari SE; Picada JN
Pharmacol Res; 2009 Jan; 59(1):57-61. PubMed ID: 18973814
[TBL] [Abstract][Full Text] [Related]
7. [Psychiatry].
Aubry JM; Delini-Stula A; Gervasoni N; Bryois C; Barbe R; Merlo M; Bertschy G
Rev Med Suisse; 2007 Jan; 3(94):161-7. PubMed ID: 17354543
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
Bomholt SF; Mikkelsen JD; Blackburn-Munro G
Neuropharmacology; 2005 Feb; 48(2):252-63. PubMed ID: 15695164
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression.
Kluge M; Schüssler P; Steiger A
Eur Neuropsychopharmacol; 2007 Jul; 17(8):527-31. PubMed ID: 17337164
[TBL] [Abstract][Full Text] [Related]
10. The role of the NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test.
Zomkowski AD; Engel D; Cunha MP; Gabilan NH; Rodrigues AL
Pharmacol Biochem Behav; 2012 Dec; 103(2):408-17. PubMed ID: 23010381
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antidepressant effects of duloxetine and bupropion by caffeine in mice.
Kale PP; Addepalli V
Pharmacol Biochem Behav; 2014 Sep; 124():238-44. PubMed ID: 24933334
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Müller N; Schennach R; Riedel M; Möller HJ
Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
[TBL] [Abstract][Full Text] [Related]
13. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice.
Fuller RW; Hemrick-Luecke SK; Snoddy HD
J Pharmacol Exp Ther; 1994 Apr; 269(1):132-6. PubMed ID: 7513356
[TBL] [Abstract][Full Text] [Related]
14. Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report.
Mari F; Gualco B; Rensi R; Bertol E
Cardiovasc Toxicol; 2012 Sep; 12(3):258-62. PubMed ID: 22351288
[TBL] [Abstract][Full Text] [Related]
15. [Duloxetine for chronic pain management: pharmacology and clinical use].
Masuda R; Itoh M; Suzuki T
Masui; 2013 Jul; 62(7):814-21. PubMed ID: 23905404
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine (Cymbalta) for diabetic neuropathic pain.
Med Lett Drugs Ther; 2005 Aug 15-29; 47(1215-1216):67-8. PubMed ID: 16103866
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.
Kasahara T; Ishigooka J; Nagata E; Murasaki M; Miura S
Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Feb; 16(1):25-31. PubMed ID: 8640460
[TBL] [Abstract][Full Text] [Related]
18. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
19. Prescribing patterns and safety monitoring of duloxetine using the Danish Register of Medicinal Product Statistics as a source.
Johansen AN; Stenzhorn AA; Rosenzweig M; Thirstrup S; Gazerani P
Scand J Public Health; 2013 Dec; 41(8):866-73. PubMed ID: 23885111
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
